MRNS (Marinus Pharmaceuticals) Other Operating Expense : $-0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Marinus Pharmaceuticals Other Operating Expense?

Marinus Pharmaceuticals's Other Operating Expense for the three months ended in Sep. 2024 was $-0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.00 Mil.

Marinus Pharmaceuticals's quarterly Other Operating Expense stayed the same from Mar. 2024 ($0.00 Mil) to Jun. 2024 ($0.00 Mil) but then declined from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($-0.00 Mil).

Marinus Pharmaceuticals's annual Other Operating Expense increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($1.17 Mil) but then declined from Dec. 2022 ($1.17 Mil) to Dec. 2023 ($0.00 Mil).

Marinus Pharmaceuticals Other Operating Expense Historical Data

The historical data trend for Marinus Pharmaceuticals's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marinus Pharmaceuticals Other Operating Expense Chart

Marinus Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Operating Expense

Get a 7-Day Free Trial

1.17

Marinus Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Operating Expense	Get a 7-Day Free Trial															-	-	-	-	-

Marinus Pharmaceuticals Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

Marinus Pharmaceuticals Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Marinus Pharmaceuticals's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Marinus Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marinus Pharmaceuticals Inc (NAS:MRNS) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Matsonford Road, Suite 500, 5 Radnor Corporate Center, Radnor, PA, USA, 19087

Website

https://www.marinuspharma.com

Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.

Executives

Elan Ezickson	director	AVEO PHARMACEUTICALS, INC., 75 SIDNEY STREET, CAMBRIDGE MA 02139
Marvin Johnson	director	C/O TREVENA, INC., 955 CHESTERBROOK BOULEVARD, STE. 110, CHESTERBROOK PA 19087
Scott Braunstein	director	C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Christina Shafer	officer: Chief Commercial Officer	5 RADNOR CORPORATE CENTER, SUITE 500, 100 MATSONFORD ROAD, RADNOR PA 19087
Martha E Manning	officer: VP, Gen. Counsel & Corp. Sec.	700 PENNSYLVANIA DR, EXTON PA 19341
Joseph Hulihan	officer: Chief Medical Officer	5 RADNOR CORP CENTER SUITE 500, 100 MATSONFORD RD, RADNOR PA 19087
Steven Pfanstiel	officer: CFO	5 RADNOR CORPORATE CENTER STE 500, 100 MATSONFORD RD, RADNOR PA 19087
Sarah B. Noonberg	director	331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Fischer Seth H.z.	director	C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Charles Austin	director	5 RADNOR CORPORATE CENTER STE 500, 100 MATSONFORD RD, RADNOR PA 19087
Christine Berni Silverstein	director	C/O ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Santiago Arroyo	director	C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Sara Nochur	director	295 WOODCLIFF RD, NEWTON MA 02461
Nicole Vitullo	director, 10 percent owner	3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Edward F Smith	officer: Chief Financial Officer	C/O POLYMEDIX, INC., 3701 MARKET STREET, PHILADELPHIA PA 19104